Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging | Alzheimer's Research & Therapy | Full Text

Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging | Alzheimer's Research & Therapy | Full Text

Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging

β-amyloid (Aβ) positron emission tomography (PET) imaging is currently the only Food and Drug Administration-approved method to support clinical diagnosis of Alzheimer’s disease (AD). However, numerous researc...

Authors:James D. Doecke, Larry Ward, Samantha C. Burnham, Victor L. Villemagne, Qiao-Xin Li, Steven Collins, Christopher J. Fowler, Ekaterina Manuilova, Monika Widmann, Stephanie R. Rainey-Smith, Ralph N. Martins and Colin L. Masters

Citation:Alzheimer's Research & Therapy 2020 12:36

Content type:Research

Published on: 31 March 2020

• ViewFull Text
 
• ViewPDF